MO HB593

Creates the "Missouri Oral Chemotherapy Parity Interim Committee" to study disparities in patient co-payments between oral and intravenously administered chemotherapy treatments.

Committee shall examine reasons for co-payment differences and patient benefits of establishing parity between oral and infused chemotherapy agents, including cost and actuarial analysis.

Committee composed of 14 members including two state senators, two state representatives, oncologists, nurses, pharmacists, pharmacy benefit managers, patient advocates, hospital and health carrier representatives, and chaired by the director of the Department of Insurance, Financial Institutions and Professional Registration.

Governor to appoint non-legislative members no later than September 1, 2013.

Committee required to submit report with study results and legislative recommendations to the governor and legislature no later than January 1, 2014.